With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. The 2024-25 Innovation Fund Seed Grants are currently open and you...
The Ted Rogers Centre for Heart Research is delighted to welcome Iris Cohn as the new Innovator in Genomic Translation - also recently promoted to Director of the Pharmacogenetics (PGx) Program at The Hospital for Sick Children. A trained pharmacist, Iris established...
NorthMiRs Inc., an innovative cardiovascular biotech start-up, has won $250,000 in funding from the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) PITCH 2024 competition. Since its launch in 2018, the ECHO...
Congenital heart disease (CHD) is the most commonly occurring birth anomaly. Despite a strong genetic basis, almost 90% of cases remain genetically undiagnosed. However, the surge of new technology is enabling a search for hidden gene defects not detectable on...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
3D models of heart failure… stiffened hearts in diabetes…. saving infant lives
After a heart attack, this peptide protects the heart from further injury
Featured Event
ECHO PITCH 2024
Virtual Library
Visit our YouTube channel filled with world-class heart failure educational sessions on diverse topics
The planning committee for the 2021 Ted Rogers Centre Heart Failure Symposium is pleased to welcome all clinicians, investigators, trainees and interested parties to join this year’s virtual meeting on Dec. 10-11, 2021. This meeting, which blends clinical innovations with the latest scientific advances, has grown to become Canada’s largest conference on heart failure.
On Friday, December 10th, our research-focused symposium examines congenital heart disease, and how we can take animal models and regenerative medicine approaches to answer the clinical challenges that remain. It also highlights commercialization success stories, and sees how innovators developed an idea and translated it to impact. And it will shine a light on unique new scientific approaches in the emerging field of cardiotoxicity.
On Saturday, December 11th, we will reprise a very popular program for primary care practitioners who manage patients with (or at risk of) heart failure, as well as other front-line health-care professionals. Experts will address a range of topics that include emerging therapies, new standards of care, nurse-led initiatives, wearable technology, comorbidities and caring for specialized populations and complex cases. This program will be submitted for accreditation.